

Evaluating molecular study of the association of Glutathione S – Transferase GST (T1 , M1) genetic polymorphism in Iraqi Arab Femals with Type 2 Diabetes Mellitus and Coronary Artery Disease

*Marwa M. Mahmood**

*Isam N. Salman***

*Nagham E. Al-Essa**

*Batool A. Shihab **

* Department of Biology, College of Science for Women, University of Baghdad.

**National Diabetic center, Al-Mustansiriyah University.

Received 18, September, 2014

Accepted 22, December, 2014



This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Abstract:

Coronary artery disease (CAD) is a major health concern and leading of death in individuals with type 2 diabetes mellitus (T2DM). Glutathione S – Transferase(GST) are known for their broad range of detoxification and in the metabolism of xenobiotics . The role of functional variants of these genes in the development of various disorder is proven. We investigated the possible role of these variants in the development of CAD in T2DM patients. In this case – control study a total of 60 patients (T2DM = 30 ; T2DM – CAD = 30) and 30 controls were included. Serum lipid profiles were measured and DNA was extracted from the blood samples. Multiplex PCR for GSTT1/M1 (present / null) polymorphism, were performed for genotyping of study participants. Gene frequency and lipid profiles were statistically analyzed for disease association. Regression analysis showed that, there was no significant difference of the frequency of GSTT1 (positive /null) genotype and GSTM1 (positive /null) genotype in the 3 study groups . GSTT1 – positive genotype is associated with a 0.51 fold increased (OR = 0.51 ; 95%CI = 2- 0.1 ;P = 0.321) , while the GSTM1 – positive genotype was associated with a 3 fold increase (OR = 3.06 ; 95%CI=1- 9.7 ; P = 0.055) .We conclude GSTT1 positive genotype considered to be a protective risk from CAD in T2DM patients . The GSTM1 – positive genotype it was considered to be a risk factor of the CAD in T2DM patients.

Key words: Coronary Artery Disease, Type 2 Diabetes Mellitus, Glutathione S-Transferase, polymerase chain reaction.

Introduction:

Cardiovascular diseases are the leading cause of mortality among Type -2 diabetes mellitus (T2DM), which has a complex etiology that includes both atherogenic and myocardial components [1]. Almost 200 million people worldwide have Type 2 diabetes mellitus[2] and it is broadly

recognized as an equivalent risk factor for coronary artery disease (CAD)[3].

The prevalence, incidence and mortality of all cardiovascular disorders (CVD) are two – to eightfold higher in persons with diabetes than in those without diabetes [4] . Reactive oxygen species (ROS) production

induced by chronic hyperglycemia is implicated as a potential molecular mechanism behind diabetic vascular complications [5]. T2DM is associated with increased production of reactive oxygen species (ROS) and a reduction in antioxidant defenses leading to oxidative [6]. Oxidative stress, arising as a result of an imbalance between free radicals and antioxidant defenses, is associated with damage to lipids, proteins and nucleic acids, which could contribute to diseases including atherosclerosis, cancer and diabetes mellitus [7].

Pancreatic β – cells have emerged as a putative target of oxidative stress induced tissue damage, and this seems to explain in part the progressive deterioration of β - cell function in type 2 diabetes mellitus [8].

Organisms have evolved many defense mechanisms as protection from these reactive intermediates (antioxidant). These include, but are not limited to, various enzymes such as glutathione S - transferase (GSTs) superoxide dismutase, Se- dependent glutathione peroxidase, catalase, glutaredoxins and peroxiredoxins [9]. Beta cells are very sensitive to cytotoxic stress because they express very little of the antioxidant enzymes. Hence, beta – cell is at greater risk of oxidative damage than other tissues with higher levels of antioxidant protection [10].

Glutathione (GSH) is the major cellular antioxidant that protects against environmental toxicants as well as reactive oxygen species (ROS) mediated cell injury. (GSH) detoxifies multiple compounds through glutathione S – transferase [11]. The glutathione S transferase (GSTs) are gene super family enzyme that detoxify free radicals [12]. This plays an important role in protecting DNA against damage by genotoxins and adducts formation [13]. GSTs protect cells against oxidative stress [14].

GSTs are a family detoxification enzymes catalyze the conjugation of toxic and carcinogenic electrophilic molecular with glutathione and thereby protect cellular macromolecules against toxic foreign chemicals and oxidative stress by free radical scavenging. Human GST enzymes are divided into three main families: cytosolic, mitochondrial and microsomal [15]. The enzyme active site is composed of two subsites, a G-site for binding GSH and an H – site for binding the hydrophobic electrophile. Based on, among others amino acid sequence identities, isoelectric points, substrate selectivities and immunological reactivities [16].

In human, glutathione S transferase super family have been assigned to least eight separate classes designated alpha, mu, kappa, omega, pi, sigma, theta and zeta, which are encoded by the GSTA, GSTM, GSTK, GSTO, GSTP, GSTS, GSTT and GSTZ genes, respectively [15].

GSTT1 and GSTM1 polymorphism are the most common polymorphism of the GST enzyme in the human population with major ethnic differences [17]. GSTs have been found in many species including: humans, rats, bacteria, yeast, molds, insects, plants, fish and birds [18]. In human, the GSTM1, gene is situated in the GSTM cluster which has been localized to chromosome one in the region (1p13.3), five mu class genes are situated (GSTM1-GSTM5) on chromosome 1 [19]. The theta class of GSTs consists of two different subfamilies: GSTT1 and GSTT2. Gene encoding both proteins are located on chromosome (22q11.2) [20].

According to the reviewed literature, few studies have been published on the association between GSTT1/GSTM1 polymorphism and susceptibility to diabetes with coronary heart disease,

and there are large divergences among the study results. This first case – control study on the Iraqi population was designed to provide more information about the effects of the GSTT1 and GSTM1 polymorphism on T2DM and CAD risk. In this study obtained important results regarding the contribution of GST polymorphisms to T2DM with CAD and without CAD.

Subjects and methods

The study consisted of 60 patients (30 T2DM and 30 T2DM with CAD) and 30 health control women. Their age range was (40 -65) years, from National – Diabetes Center, Al – Mustansiriya University.

Collection of blood samples:

From each patient groups and healthy human, (5ml) of blood was obtained by vein puncture using (5ml) disposable syringes after (12-14) hours fasting. The blood sample was divided into two aliquots: (3ml) and (2ml). The first aliquot (3ml) is dispensed in a plain test tube and left for around an hour to clot at room temperature, and then separated by centrifugation at (3000 rpm) for (10 min) to collect serum. The separated serum used for assays of lipid profile and fasting plasma glucose.

Genomic DNA extraction and genotyping:

Genomic DNA was isolated from (2 ml) whole blood collected in the EDTA tubes using the Wizard genomic DNA purification kit (Promega, USA) (Figure 1), Albumin as an internal control. PCR amplifications were performed in a total volume of 50µL containing 5µl genomic DNA, 14µl D.W., 25µl master mix and 1µl of each primer. as follows: GSTM1 were: 5' GAA CTC CCT GAA AAG

CTAAAG C 3', 5' GTT GGG CTC AAA TAT ACG GTG G 3'. The GSTT1 F: 5' TTC CTT ACT GGT CCT CACATC TC 3' and GSTT1 R: TCA CCG GAT CATGGC CAG CA 3'. The primers for albumin were Alb F: 5' GCC CTC TGC TAA CAA GTC CTA C 3' and Alb R: 5' GCC CTA AAA AGA AAA TCG CCAATC 3', Thermal cycling conditions include: an initial denaturation step at 95°C for 3 min, 30 cycles at 94 °C for 1 min, 59 °C for 1 min and 72 °C for 1 min, and a final extension step at 72°C for 5 min. The amplification products were size separated on 2% agarose gels and visualized by ethidium bromide staining (5%). GSTM1 and GSTT1 genotypes were determined by the presence and absence (null) of bands of 210 bp and 480 bp, respectively, with an internal control of 260 bp.

Using this genotyping assay of GSTM1 and GSTT1, the null genotypes can be clearly categorized, but the heterozygote and homozygote positive genotypes could not be differentiated [21] (Figure 2).



Fig. (1): Agarose electrophoresis of the genomic DNA sample. Fragments were fractionated by electrophoresis on 0.8% agarose (1h/70v), 1Xtb (tri-borate buffer) and visualized by ethidium bromide staining.




Fig. (2): A representative multiplex PCR analysis of GSTs polymorphism. GSTM₁ and GSTT₁ genes PCR products resolved by (2%) agarose gel electrophoresis (1h/70v). Lane M, DNA molecular weight marker. Lane B, negative control. Lane (1.13) is samples. A 350 pb DNA fragment corresponding to the albumin gene product provides an internal positive control for each reaction and can be seen in all PCR reaction. A 215 pb is present only in those individuals containing the GSTM₁ gene while a 480 pb products is present only in those individuals containing the GSTT₁ gene.

Statistical analysis:

Data of continuous variables were expressed as mean ± Standard Deviation (SD) and data of non continuous variables as frequency (N%) .The data for three or more independent groups were evaluated by analysis of variance (ANOVA). The genetic variants and their risk for disease were computed by odd ratio (OR) and 95%CI Confidence Intervals by logistic regression analysis.

Results:

Table 1 shows the positive of the GSTT1 gene occurs higher frequencies in healthy controls 26(86.7%), than patients T2DM without CAD 25(86.2%) and patients T2DM with CAD 23(76.7%) , p= 0.51 there was no significant difference between three study groups .

While the GSTM1 shows the higher frequencies in T2DM with CAD 13(43.3%), than patients T2DM

without CAD 9(31%) and healthy control 6(20%). There was no significant difference between them.

Table 1: Comparison of GST genotypes among three population

Genotype	Healthy Controls n=30 N %)	T2DM n=30 N(%)	T2DM+CAD n=30 N(%)	P(value)
GSTT1 Positive null	25 (86.7%) 4(13.8%)	25(86.2%) 5(13.8%)	23(76.7%) 7(23.3%)	0.51
GSTM1 Positive null	6(20%) 21(80%)	9(31%) 21(69%)	13(43.3%) 17(56.7%)	0.15

Significant difference p>0.05 , non significant p<0.05

Association of GST polymorphism with T2DM and CAD

In the (table 2) showed the risk estimates for CAD among the diabetic patients .GSTT1 positive genotype was associated with 0.66 but the GSTM1 positive genotype was associated with 1.78 – fold . There was no significant difference between them .There was no risk found for (GSTT1and GSTM1) null genotypes. We observed that the GSTT1 positive genotype was considered to be a protective risk because of the rate of OR = less than one.

But the GSTM1 positive genotype was considered a risk factor to development the CAD in T2DM patients because of the rate of OR = more than one.

(Table 2) The risk of having T2DM with CAD in the presence of two genes compared to cases having T2DM without CAD.

Genotype	T2DM n=30 N %)	T2DM+CAD n=30 N(%)	OR	95 % CI	P(value)
GSTT1 Positive null	25 (86.7%) 5(13.8%)	23(76.7%) 7(23.3%)	0.6 6 Ref	2.4- 0.2	0.52
GSTM1 Positive null	9(31%) 21(69%)	13(43.3%) 17(56.7%)	1.7 8 Ref	0.6- 5.2	0.286

OR – odds ratio and CI – confidence interval from conditional logistic regression analysis.

(Table 3) The risk of having T₂DM with CAD in the Presence of two genes compared to cases T₂DM without CAD

Genetic Composition	T2DM n=30 N(%)	T2DM+CAD n=30 N(%)	OR	95% CI	P(alue)
GSTT1-/GSTM1-	3 (10.3%)	2 (6.7%)	Ref	-	-
GSTT1+/GSTM1-	17(58.6%)	15(50.0%)	1.32	0.2-9	0.797
GSTT1-/GSTM1+	1(3.4%)	5(16.7%)	7.5	0.5-122.7	0.143
GSTT1+/GSTM1+	2(27.6%)	8(26.7%)	1.5	0.2-11.5	0.708
Total	30(100%)	30(100%)			

In Table 3, the distribution analysis for the both GSTT1 and GSTM1 genotypes can be observed. There was a low frequency of individuals who had a double null genotype (-/-), for both T2DM without CAD patients and T2DM with CAD patients (10.3% and 6.7%, respectively).

A higher prevalence of individuals with a GSTT1 present / GSTM1 null for both groups (58.6% and 50.0%, respectively) was also observed.

Discussion:

Diabetes Mellitus is one of the most common chronic diseases in nearly all countries, the number of people with diabetes is increasing due to population growth, aging, urbanization and increasing prevalence of obesity and reduced physical activity [22]. T2DM is a major risk factor for coronary artery disease (CAD) resulting in high morbidity and mortality [23]. Imbalance between free radicals and anti-oxidant defenses is associated with cellular dysfunctions leading to the pathophysiology of various diseases [7]. Experimental evidence suggests that diabetes is associated with a reduced overall antioxidant defense system [24] and the increased oxidative stress may contribute to the pathogenesis of the diabetic complications, notably the emergence of premature

atherosclerosis [25]. The role of oxidative stress in the development of coronary artery disease is well known [26].

Our study showed there was no significant difference between three study groups which agree with Hussain et al., (2012) who found there was no significant difference between GSTT1(positive/null), $P=0.157$ as well as between GSTM1(positive/null), $P=0.360$ in patients and controls. While Ramprasath et al., (2011) who found the GSTT1 positive genotype occurs at higher frequencies in controls than in T2DM with CAD and T2DM without CAD patients, but the GSTM1 positive genotype occurs at higher frequencies in controls than in T2DM with CAD patients and T2DM without CAD patients, there were significant difference between three study groups in two status of GSTs (T1, M1) with CAD.

This study showed the distribution of GST genotype and alleles of the patients groups were given, the GSTT1 positive genotype occurs at higher frequencies in T2DM without CAD than in T2DM with CAD, while the GSTM1 positive genotype occurs at higher frequencies in T2DM with CAD patients than in T2DM without CAD patients.

Previous studies regarding the association between GST polymorphism and cardiovascular diseases have also shown conflicting results, with striking differences between ethnic groups [27,28]. These results which disagreement with Pinheiro et al., (2013) who found that the GSTT1 null genotype ($p=0.0004$) is related to an increased predisposition for T2DM, conferring a 3.2 fold increased risk of developing the disease relative to the present genotype. It was also observed that there wasn't any association of the GSTM1 null genotype with

susceptibility to disease in the population studied (OR = 1.1, 95%CI = 0.66-1.82, P = 0.732). On the contrary, similar study in the Turkish population reported that both GSTT1 and GSTM1 null genotype were associated with increased coronary artery disease, which became statistically significant only with smoking [27]. Another Indian study has complicated it further, reporting that the GSTT1 null genotype is protective against coronary artery disease [28]. Given all these conflicting results, one might think that the detoxification capacity of oxidative stress does not simply parallel the lowering of cardiovascular risks.

Our results are lower frequency of individuals who had a double null genotype (-/-) , for both patient groups (T2DM without CAD and T2DM with CAD) was (10.3%) and (6.7%) respectively .A higher prevalence of individuals with a GSTT1present /GSTM1 null for both groups (58.6%) /(50.0%) respectively . According to these results we consider the (GSTM1+) genotype a risk factors to developed the CAD in T2DM patients. These results agreement with some researches which reported that the GSTT1 genotype reduces the incidence rate of type 2 diabetes mellitus and might be a protective factor[29,30].

This may be the first study of association between T2DM, CAD and GSTs polymorphism in Iraqi population .Our results found that the GSTT1(+) genotype was protective factor for having T2DM or CAD while GSTM1 positive genotype was a risk factor for T2DM and CAD by increasing 1.78 fold. This finding didn't agreement with other studies.

It is difficult to determine the role of polymorphism of different proteins involved in the inflammation in CAD . The studies of this kind have limitation in establishing the causal role in the

disease. However, these studies contribute to the scientific evidence in elucidating the etiology of complex multifactorial diseases like CAD and hopefully provide a step in the search for candidate genes.

Conclusion: Our results suggest that GSTM1 gene polymorphisms may play an important role to development CAD in T2DM patients.

References:

- [1] Fang, Z. Y.; Prins, J. B and Marwick. T. H. 2004. Diabetic cardiomyopathy:evidence, mechanisms, and therapeutic implications , *Endocr . Rev.*25, 543 -567.
- [2] Wild, S.; Roglic, G.; Green, A.; Sicree, R. and King, H. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 27: 1047 – 1053.
- [3] Jouven, X.; Lemaitre, R. N.; Rea, T. D.; Sotoodehnia, N.; Empana, J. P. and Siscovick DS. 2005. Diabetes, glucose level, and risk of sudden cardiac death. *Eur Heart J* 26:2142 – 2147 .
- [4] Grundy, S. M.; Howard, B.; Smith, S. J. R.; Eckel, R.; Redberg, R. and Bonow, R. O. 2002. Prevention conference VI: diabetes and cardiovascular disease. executive summary conference proceeding for health care professionals from a special writing group of the American heart association 105:2231- 2239 .
- [5] Ramprasath, T.; Murugan, P. S.; Kalaiarasan, E.; Gomath, P.; Rathinavel, A. and Selvam, G. S. 2011. genetics association of glutathione peroxidase (GPx-1) and NAD(P) H : Quinone oxidoreductase 1(NQO1) variants and their association of CAD in patients with type 2 – diabetes.

- [6] Mahmed, A.; Amer, Maivel H. Ghattas, Dina M. Abo- Elmatty, and Soad H, Abo El –Ela. 2012. Evaluation of glutathione S-transferase P1 genetic variants affecting type 2. *Journal List .Arch Med Sa. v .8(4); Sep 2102 .*
- [7] West, J. C., 2000 .Radicals and oxidative stress in diabetes . *Diabet. Med ,17:171-180.*
- [8] Gorogawa S, Kajimoto Y., Umayahara Y., Kaneto H. 2002. Probulcol preserves pancreatic beta – cell function through reduction of oxidative stress in type 2 diabetes . *Diabetes Res Clin . Pract ., 57 : 1-10 .*
- [9] Hayes JD , Flanagan JU and Jowsey IR. 2005. Glutathione transferase . *Annu Rev Pharmacol Toxicol; 45:51-88.*
- [10] Robertson , R.P., Harmon . J , Tran .P.O, Tanaka .Y , Takahashi .H. 2003. Glucose toxicity in beta – cells: type 2 diabetes, good radicals gone bad, and the glutathione connection *Diabetes, 52 : 581- 587 .*
- [11] Bekris, L. M.; Shephard .C.; Peterson, M.; Hoehna, J.; Van .B Yserloo , Rutledge, E.; Farin, F.; ,Kavanagh, T. J. and Lernmark, A. 2005. Glutathione S- transferase M 1 and T1 polymorphisms and association with type 1 diabetes age - at – onset autoimmunity. *38(8): 567 – 75.*
- [12] Li, R.; Boerwinkle, E.; Olshan, A.F et al . 2000. Glutathione S-transferase genotype as susceptibility factor in smoking – related coronary heart disease. *atherosclerosis, 149: 451-462 .*
- [13] Ryberg, D.; Skaug, V.; Hewer, A.; Philipps, DH.; Harries, LW.; Wolf, CR.; et al . 1997. Genotypes of glutathione transferase M1and P1 and their significance for Lung DNA adduct levels and cancer risk *cardinogenesis , 18: 1258- 9 .*
- [14] Amer, MA.; Ghattas, MH.; Abo – Elmatty, DM. and Abou - el- Ela, SH. 2011. Influence of glutathione S – transferase polymorphisms on type 2 diabetes mellitus risk. *Genet Mol Res 10: 3722 – 30 .*
- [15] Hayes, JD. and Strande, R.C. 2000. Glutathione S- transferase polymorphisms and their biological consequence. *Pharmacology; 61: 154 – 166.*
- [16] Van der Aar, E.M.; Bouwman, T.; Commandeur, J. N. and Vermeulen, N. P. 1996. Structure – activity relationships for chemical and glutathione S-transferase – catalysed glutathione conjugation reactions of a series of 2 – substituted 1 – chloro-4-nitrobenzenes. *Biochem.J., 320: 531- 540 .*
- [17] Nowier, SH. R, Nada K. Kashmiry; Hoiyda A . Abdel; Rasool , Heba Morad and Somaia Ismail 2009 . Association of type 2 diabetes mellitus and glutathione S- transferase (GSTM1 and GSTT1) genetic polymorphisms. *Reserch Journal of Medicine and Medical Sciences, 4(2) : 181-188.*
- [18] Hayes, J. and Pulford, D .1995. The glutathione S- transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprevention and drug resistance. *Crit. Rev. Biochem .Mol . Biol., 30 , 445 – 600 .*
- [19] Mclellan, R. A.; Oscarson, M.;; Alexandrie A.K.; Seidegard, J.; Evans, D. A.; and Ranning, A. 1997. Charaterization of human glutathione S- transferase M cluster conaining of duplicated enzyme activity .*Mol . Pharmacol ., 52 : 958 – 965.*
- [20] Pemples, S.; Schroeder, K. R.; Spencer, S. R.; Meyer, D. J.; Hallier, E. and Bolt , H.M. 1994. Human glutathione S- transferase

- theta (GSTT1) Cdna cloning and the characterization of a genetic polymorphism. *Biochem J.*, 300:271- 276.
- [21] Arand, M.; Muhlbanuer, R.; Hengstler, J.; Jager, E.; Fuchs, J. and Wnkler, L. 1996. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. *Anal Biochem* , 236 : 184-86.
- [22] Wild, S.; Roglic, G.; Green, A. and Sicree, R. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 . *Diabetes Care*, 27:1047-1053.
- [23] Lago, RM. and Nesto, RW. 2009. Type 2 diabetes and coronary heart disease: focus on myocardial infarction. *Curr Diab Rep* 9:73-78.
- [24] Kim, J.; Chehade, J.; Pinnas, JL. and Mooradian, AD. 2000. Effect of select antioxidants on malondialdehyde – modification of proteins. *Nutrition* 16:1079-1081 .
- [25] Rosen, P.; Nawroth, PP.; King, G.; Moller, W.; Tritschler, HJ.; Packer, L. 2001. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. *Diabetes Metab Res Rev* 17:189-212 .
- [26] Soydinc, S.; Celik, A. and Demiryurek S. 2007. The relationship between oxidative stress, nitric oxide, and coronary artery disease. *Eur J Gen Med* 38:62-66.
- [27] Tamer, L.; Ercan, B.; Camsari, A.; Yildirim, H.; Cicek, D.; Sucn, N.; Ates, N. A. and Atik, U. 2004. Glutathione S–Transferase gene polymorphism as a susceptibility factor in smoking – related Coronary Artery Disease. *Basic Res. cardiol.*, 99, 223 – 229.
- [28] Girisha, K. M., Gilmour A., Mastana S., Singh V.P., Sinho N., Tewari S., Ramesh V., Sankar V.H., Agrawal S . 2004 . T1 and M1 glutathione S- transferase gene and coronary artery disease in North Indian population . *Indian Journal of Medical Sciences* . 58:12-15.
- [29] Pinheiro, Cesar R.; Denise, S.; Rocha Filho.; Claudia A. Mundium.; Paulo de Marco Junior.; Cirano J. Ulhoa.; Angela A. S. Reis and Paulo C. Ghedini 2013. Evaluation of glutathione S-transferase GSTT1 and GSTM1 deletion polymorphisms on Type – 2 diabetes mellitus risk . *PLoS ONE* 8(10) : e7626 .
- [30] Wang L. and Zhang, Q. Li. 2006. Genetic polymorphisms of GSTT1, GSTM1 and NQO1 genes and diabetes mellitus risk in Chinese population. *Biochemical and physical research communications* 341:310-313.

تقييم الدراسة الجزيئية للعلاقة بين الجلوتاثيون اس – ترانسفيريز (T1,M1) في الإناث العراقيات العربيات مصابات بداء السكري من النوع الثاني و أمراض الشرايين القلبية التاجية

نغم عيسى العيسى*
بتول علي شهاب*

مروة محي الدين محمود*
عصام نوري سلمان**

*قسم علوم الحياة، كلية العلوم للبنات، جامعة بغداد.
**المركز الوطني لأبحاث وعلاج السكري، الجامعة المستنصرية.

الخلاصة:

مرض الشرايين القلبية التاجية من المخاطر الصحية الخطرة و التي تؤدي الى وفاة الاشخاص المصابين بداء السكري من النوع الثاني . انزيم الجلوتاثيون اس – ترانسفيريز واسع المدى في ازالة السمية و الاستقلاب الايضي . ثبت دور المتغيرات الوظيفية من هذه الجينات في تطوير مختلف الاضطرابات المرضية . لذلك في هذه الدراسة تحرينا عن الدور المحتمل لهذه المتغيرات في تطوير امراض الشرايين القلبية في المرضى المصابين بداء السكري من النوع الثاني . في هذه الحالة تمت الدراسة على مجموعه من ٦٠ مريضا (٣٠ مريض بالسكري فقط و ٣٠ مريض مصابين بالسكري و امراض القلب) و ٣٠ من الاناث الاصحاء . تم قياس الدهون الخماسية و تم استخلاص الدنا (DNA) من عينات الدم و تم عمل ال PCR للكشف عن جينات GSTT1 and GSTM1 و اظهرت التحليلات الاحصائية بعدم وجود اختلافات معنوية بين المجاميع الثلاثة بالنسبة لوجود او عدم وجود الجينات . اظهرت التحليلات الاحصائية بان وجود الجين GSTT1 يرتبط بمعدل $OR = 0.51$ بينما وجود الجين GSTM1 يرتبط بمعدل $OR = 3.6$ وهذا يدل على أن وجود الجين GSTT1 لدى مرضى السكري كعامل وقاية ضد الإصابة بالأمراض القلبية. ان وجود الجين GSTM1 يعتبر عامل خطر للإصابة بالأمراض القلبية في الاشخاص المصابين بداء السكري من النوع الثاني .

الكلمات المفتاحية: مرض الشرايين القلبية التاجية، مرض السكري من النوع الثاني، كلوتاثايون S- ترانسفيريز، تفاعل السلسلة المتعدد.